Literature DB >> 26894608

Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology.

Hoon Kook1, Nack-Gyun Chung2, Hyoung Jin Kang3, Ho Joon Im4.   

Abstract

The treatment of choice for aplastic anemia (AA) in children has been HLA-matched family donor (MFD) hematopoietic stem cell transplantation (HSCT). For those lacking MFD, immunosuppressive therapy (IST) consisting of horse antithymocyte globulin (ATG) and cyclosporine has been successful. The choices of second and third line treatments are more complex and debatable, especially in the situation of unavailability of horse ATG. IST with rabbit ATG seems to be less effective. Recently, improved survival of non-MFD HSCTs has been documented. The outcome of matched or mismatched unrelated donor, umbilical cord blood, or haploidentical family donor transplantations will be discussed in AA children after IST failure. Experimental approaches of upfront HSCT using non-MFDs will be briefly touched. In this review, a treatment guideline for children with AA from the Korean Society of Pediatric Hematology Oncology will be presented along with a brief review of literature on current clinical practices in Korea.

Entities:  

Keywords:  Aplastic anemia; Children; Guidelines; Hematopoietic stem cell transplantation; Immunosuppressive treatment

Mesh：

Substances：

Year:  2016        PMID： 26894608     DOI： 10.1007/s12185-016-1956-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  52 in total

1.  Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia.

Authors:  Hiroshi Yagasaki; Seiji Kojima; Hiromasa Yabe; Koji Kato; Hisato Kigasawa; Hisashi Sakamaki; Masahiro Tsuchida; Shunichi Kato; Takakazu Kawase; Yasuo Morishima; Yoshihisa Kodera
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

2.  Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.

Authors:  A Bacigalupo; F Locatelli; E Lanino; J Marsh; G Socié; S Maury; A Prete; A Locasciulli; S Cesaro; J Passweg
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

3.  Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant.

Authors:  Carlo Dufour; Marta Pillon; Gerard Sociè; Alicia Rovò; Elisa Carraro; Andrea Bacigalupo; Rosi Oneto; Jakob Passweg; Antonio Risitano; Andrè Tichelli; Regis Peffault de Latour; Hubert Schrezenmeier; Britta Hocshmann; Christina Peters; Austin Kulasekararaj; Anja Van Biezen; Sujith Samarasinghe; Ayad Ahmed Hussein; Mouhab Ayas; Mahmoud Aljurf; Judith Marsh
Journal:  Br J Haematol       Date:  2015-02-14       Impact factor: 6.998

Review 4.  Haploidentical transplantation in patients with acquired aplastic anemia.

Authors:  F Ciceri; M T Lupo-Stanghellini; E T Korthof
Journal:  Bone Marrow Transplant       Date:  2013-01-07       Impact factor: 5.483

5.  Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study.

Authors:  I Esteves; C Bonfim; R Pasquini; V Funke; N F Pereira; V Rocha; Y Novis; C Arrais; V Colturato; M P de Souza; M Torres; J F Fernandes; F R Kerbauy; A A F Ribeiro; F P S Santos; N Hamerschlak
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

6.  Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia.

Authors:  Phillip Scheinberg; Olga Nunez; Neal S Young
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

7.  Double cord blood transplantation in patients with high risk bone marrow failure syndromes.

Authors:  A Ruggeri; R Peffault de Latour; V Rocha; J Larghero; M Robin; C A Rodrigues; R Traineau; P Ribaud; C Ferry; A Devergie; E Gluckman; G Socié
Journal:  Br J Haematol       Date:  2008-08-10       Impact factor: 6.998

8.  Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

Authors:  Seiji Kojima; Takaharu Matsuyama; Shunichi Kato; Hisato Kigasawa; Ryoji Kobayashi; Atsushi Kikuta; Hisashi Sakamaki; Koichiro Ikuta; Masahiro Tsuchida; Yasutaka Hoshi; Yasuo Morishima; Yoshihisa Kodera
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

9.  Unrelated donor cord blood transplantation for non-malignant disorders in children and adolescents.

Authors:  Meerim Park; Young Ho Lee; Hae-Ryong Kang; Ji Won Lee; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn; Hee Jo Baek; Hoon Kook; Tai Ju Hwang; Jae Wook Lee; Nack-Gyun Chung; Bin Cho; Hack-Ki Kim; Soo Hyun Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Kyung Nam Koh; Ho Joon Im; Jong Jin Seo; Jun Eun Park; Yeon Jung Lim; Chuhl Joo Lyu; Jae Min Lee; Jeong Ok Hah
Journal:  Pediatr Transplant       Date:  2013-12-30

10.  Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.

Authors:  J C Marsh; R M Pearce; M B C Koh; Z Lim; A Pagliuca; G J Mufti; J Perry; J A Snowden; A J Vora; R T Wynn; N Russell; B Gibson; M Gilleece; D Milligan; P Veys; S Samarasinghe; M McMullin; K Kirkland; G Cook
Journal:  Bone Marrow Transplant       Date:  2013-08-05       Impact factor: 5.483
View more
  3 in total

1.  A New Immunosuppressive Therapy for Very Severe Aplastic Anemia in Children with Autoantibodies.

Authors:  Zhong-Jian Wang; Hong-Bo Chen; Fen Zhou; Hui Yu; Xiao-Yan Wu; Ya-Qing Shen; Yi-Ning Qiu; Run-Ming Jin
Journal:  Curr Med Sci       Date:  2022-03-08

Review 2.  Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT).

Authors:  Raheel Iftikhar; Parvez Ahmad; Regis de Latour; Carlo Dufour; Antonio Risitano; Naeem Chaudhri; Ali Bazarbachi; Josu De La Fuente; Britta Höchsmann; Syed Osman Ahmed; Usama Gergis; Alaa Elhaddad; Constantijn Halkes; Bassim Albeirouti; Sultan Alotaibi; Austin Kulasekararaj; Hazzaa Alzahrani; Tarek Ben Othman; Simone Cesaro; Ali Alahmari; Rawad Rihani; Salem Alshemmari; Amir Ali Hamidieh; Mohamed-Amine Bekadja; Jakob Passweg; Murtadha Al-Khabori; Walid Rasheed; Andrea Bacigalupo; Qamar-Un-Nisa Chaudhry; Per Ljungman; Judith Marsh; Riad El Fakih; Mahmoud Aljurf
Journal:  Bone Marrow Transplant       Date:  2021-05-19       Impact factor: 5.483

3.  Better Failure-Free Survival and Graft-versus-Host Disease-Free/Failure Free Survival with Fludarabine-Based Conditioning in Stem Cell Transplantation for Aplastic Anemia in Children.

Authors:  Seung Hwan Im; Bo Ram Kim; Soo Min Park; Bo Ae Yoon; Tai Ju Hwang; Hee Jo Baek; Hoon Kook
Journal:  J Korean Med Sci       Date:  2020-02-24       Impact factor: 2.153
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.